Figure 1.



a.
1 285 345
2 285 360
3 285 375
4 285 390
5 285 405
6 285 420
7 361 435
8 361 450
9 361 465
10 361 480
11 421 495
12 421 510
13 421 525
14 421 540
HA2 331 540
b.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
20 kDa
15 kDa
10 kDa
c.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
20 kDa
10 kDa

Figure 2




Figure 3




Figure 4a



120
100
80
60
40
20
0
Percent Survival
10mg/kg of 1C9 mAb
5mg/kg of 1C9 mAb
PBS Control
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days post challenge
Post treatment

Figure 4b



120
100
80
60
40
20
0
Percent Survival
10mg/kg of 1C9 mAb
5mg/kg of 1C9 mAb
PBS Control
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days post challenge
Post treatment

Figure 4c



105
100
95
90
85
80
75
70
65
60
Percent body weight
10 mg/kg of 1C9 mAb
5 mg/kg of 1C9 mAb
PBS Control
*
0
2
4
6
8
10
12
14
16
Post treatment
Days pre/post challenge

Figure 4d



120
100
80
60
40
20
0
Percent Survival
10mg/kg of 1C9 mAb
5mg/kg of 1C9 mAb
PBS Control
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days post challenge
Post treatment

Figure 4e



120
100
80
60
40
20
0
Percent Survival
10mg/kg of 1C9 mAb
5mg/kg of 1C9 mAb
PBS Control
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days post challenge
Post treatment

Figure 4f



105
100
95
90
85
80
75
70
65
60
Percent body weight
10 mg/kg of 1C9 mAb
5 mg/kg of 1C9 mAb
PBS Control
*
*
0
2
4
6
8
10
12
14
16
Post treatment
Days pre/post challenge

Figure 5a



120
100
80
60
40
20
0
Percent Survival
10mg/kg of 1C9 mAb
5mg/kg of 1C9 mAb
PBS Control
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Days pre/post challenge
Pre treated

Figure 5b



120
100
80
60
40
20
0
Percent Survival
10 mg/kg of 1C9 mAb
5 mg/kg of 1C9 mAb
PBS Control
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Pre treated
Days pre/post challenge

Figure 5c



105
100
95
90
85
80
75
70
65
60
Percent body weight
10 mg/kg of 1C9 mAb
5 mg/kg of 1C9 mAb
PBS Control
*
-2
0
2
4
6
8
10
12
14
Pre treated
Days pre/post challenge

Figure 6a




10
8
6
4
2
0
Log (Number of copies)/400 ng of RNA
WT (Untreated)
5 mg/kg 1C9
10 mg/kg of 1C9
***
***
***
& &
2
4
10
Days post viral challenge

Figure 6b


10
8
6
4
2
0
Log (Number of copies)/400 ng of RNA
WT (Untreated)
5 mg/kg 1C9
10 mg/kg of 1C9
***
***
***
#
&
2
4
10
Days post viral challenge

SEQUENCE LISTING

<110> Temasek Life Sciences Laboratory

<120> Monoclonal Antibodies Specific to the Fusion Peptide from Hemagglutinin from Influenza A Viruses and Uses Thereof

<130> FP4477

<160> 2

<170> PatentIn version 3.4

<210> 1
<211> 24
<212> DNA
<213> Artificial

<220>
<223> Forward Primer

<400> 1
gaaatcaaac agattagtcc ttgc 24

<210> 2
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Reverse Primer

<400> 2
cctgccatcc tccctctata aa 22

ATCC

10801 University Boulevard • Manassas, VA 20110-2209 USA • Telephone: 703-365-2700 • FAX: 703-334-2932

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.

To: (Name and Address of Depositor or Attorney)
Temasek Lifesciences Laboratory
ATTN: Jimmy Kwang
1 Research Link
National University of Singapore
Singapore

Deposited on Behalf of: Temasek Lifesciences Laboratory

Date of Receipt of Cultures by the ATCC®: November 06, 2007

Identification Reference by Depositor:		ATCC® Patent Deposit Designation:
Mouse Hybridoma	1G5 mAb	PTA-8756
Mouse Hybridoma	5F8 mAb	PTA-8757
Mouse Hybridoma	1B12 mAb	PTA-8758
Mouse Hybridoma	1C9 mAb	PTA-8759

The deposits were received by this International Depository Authority and have been accepted.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC® is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the deposit should die or be destroyed during the effective term of the patent, it shall be your responsibility to replace it with viable material. It is also your responsibility to supply a sufficient quantity for distribution for the deposit term. ATCC® will distribute the material for 30 years or 5 years following the most recent request for the deposit, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

We will inform you of requests for the strains for 30 years from date of deposit.

The deposits were tested November 21, 2007 and on that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA, USA

Signature of person having authority to represent ATCC®:

Latha Ramakrishnan

Digitally signed by Latha Ramakrishnan
DN: cn=Latha Ramakrishnan, o=ATCC, ou=IP,Licensing and Services, email=lramakrishnan@atcc.org, c=US
Date: 2007.12.19 14:44:16 -05'00'

ATCC® Patent Depository

November 21, 2007
Date

cc: Figg Rothwell